STOCK TITAN

Corcept Therapeutics Inc - CORT STOCK NEWS

Welcome to our dedicated page for Corcept Therapeutics news (Ticker: CORT), a resource for investors and traders seeking the latest updates and insights on Corcept Therapeutics stock.

Corcept Therapeutics Incorporated (NASDAQ: CORT) is a leader in developing cortisol-modulating therapies for metabolic, oncologic, and neuropsychiatric disorders. This page serves as the definitive source for verified news and regulatory updates about the company.

Access real-time press releases, clinical trial developments, and financial disclosures essential for tracking CORT's progress in pharmaceutical innovation. Our curated collection includes updates on GR antagonist research, FDA communications, and partnership announcements.

Key content categories include quarterly earnings reports, drug approval milestones, scientific conference presentations, and strategic collaborations. Investors will find timely information about Korlym® commercialization and pipeline advancements across 300+ proprietary compounds.

Bookmark this page for direct access to Corcept's official communications. Check regularly for updates on hypercortisolism treatments, oncology trials, and novel therapeutic applications of glucocorticoid receptor science.

Rhea-AI Summary
Corcept Therapeutics Incorporated (CORT) reported preliminary, unaudited, financial results for the quarter- and year-ended December 31, 2023, provided 2024 revenue guidance, and announced a stock repurchase program. Fourth quarter revenue increased by 31% to $135.4 million, and full year 2023 revenue increased by 20% to $482.4 million. The company also announced a 2024 revenue guidance of $600 – $630 million and a $200 million stock repurchase program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.1%
Tags
buyback
-
Rhea-AI Summary
Corcept Therapeutics Incorporated (CORT) announces disappointing court decision regarding patent infringement by Teva Pharmaceuticals, plans to appeal vigorously
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.62%
Tags
none
-
Rhea-AI Summary
Corcept Therapeutics Incorporated (NASDAQ: CORT) reported a 22% increase in revenue for the third quarter of 2023, reaching $123.6 million. The company also raised its 2023 revenue guidance to $470 - $480 million. Net income per common share was $0.28 (diluted), compared to $0.30 in the same period last year. Corcept's cash and investments stood at $414.8 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.97%
Tags
Rhea-AI Summary
Corcept Therapeutics Incorporated has appointed Monica Tellado as President, Emerging Markets. She will be responsible for global commercial lead in therapeutics in metabolism and neurology. Corcept also announced the initiation of a Phase 2b trial of its selective cortisol modulator miricorilant and expects results from its Phase 2 DAZALS study next year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
management acquisition
-
Rhea-AI Summary
Corcept Therapeutics has announced the initiation of MONARCH, a Phase 2b trial of miricorilant in patients with non-alcoholic steatohepatitis (NASH). The trial will evaluate the efficacy and safety of miricorilant in adult patients with biopsy-confirmed NASH, with the primary endpoint being reduction in liver fat.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
-
Rhea-AI Summary
Corcept Therapeutics to report Q3 financial results and provide corporate update on November 1, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
Rhea-AI Summary
Corcept Therapeutics reports Q2 2023 revenue of $117.7 million, a 14% increase from Q2 2022. Raises 2023 revenue guidance to $455-$470 million. Net income per share of $0.25 (diluted). Cash and investments of $363.3 million as of June 30, 2023. Purchase of 6.6 million shares of Corcept common stock for $145.4 million. Enrollment completed in Phase 3 GRACE trial of relacorilant for Cushing's syndrome. Positive feedback on CATALYST trial. Enrollment continues in ROSELLA trial for ovarian cancer. Enrollment continues in DAZALS trial for ALS. Enrollment continues in Phase 1b trial of miricorilant for NASH. Conference call on August 2, 2023, at 5:00 p.m. Eastern Time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.91%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
-
Rhea-AI Summary
Corcept Therapeutics announces positive results from Phase 1b study of miricorilant in NASH patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
none
Corcept Therapeutics Inc

Nasdaq:CORT

CORT Rankings

CORT Stock Data

7.52B
93.36M
11.44%
81.8%
15.21%
Biotechnology
Pharmaceutical Preparations
Link
United States
REDWOOD CITY